Pasar al contenido principal

ESTUDIO DE NUEVOS BIOMARCADORES FISIOLOGICOS Y TUMORALES ASOCIADOS A LA DIANA TERAPUTICA PLK1

PID2021-125705OB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2021
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Lights and Shadows on the Cancer Multi-Target Inhibitor Rigosertib (ON-01910.Na)

  • Monfort-Vengut, Ana
  • Cárcer, Guillermo de
Rigosertib (ON-01910.Na) is a small-molecule member of the novel synthetic benzyl-styryl-sulfonate family. It is currently in phase III clinical trials for several myelodysplastic syndromes and leukemias and is therefore close to clinical translation. The clinical progress of rigosertib has been hampered by a lack of understanding of its mechanism of action, as it is currently considered a multi-target inhibitor. Rigosertib was first described as an inhibitor of the mitotic master regulator Polo-like kinase 1 (Plk1). However, in recent years, some studies have shown that rigosertib may also interact with the PI3K/Akt pathway, act as a Ras–Raf binding mimetic (altering the Ras signaling pathway), as a microtubule destabilizing agent, or as an activator of a stress-induced phospho-regulatory circuit that ultimately hyperphosphorylates and inactivates Ras signaling effectors. Understanding the mechanism of action of rigosertib has potential clinical implications worth exploring, as it may help to tailor cancer therapies and improve patient outcomes., This research was funded by the Spanish Ministry of Science and Innovation MCIN/AEI/FEDER (doi:10.13039/501100011033), grants RTI2018-095496-B-I00 and PID2021-125705OB-I00, and by the Spanish Association Against Cancer (AECC) Scientific Foundation, grant LABAE16017DECA., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Whole-Genome Doubling as a source of cancer: how, when, where, and why?

  • Sanz-Gómez, Natalia
  • González-Ávarez, María
  • De Las Rivas, Javier
  • Cárcer, Guillermo de
Chromosome instability is a well-known hallmark of cancer, leading to increased genetic plasticity of tumoral cells, which favors cancer aggressiveness, and poor prognosis. One of the main sources of chromosomal instability are events that lead to a Whole-Genome Duplication (WGD) and the subsequently generated cell polyploidy. In recent years, several studies showed that WGD occurs at the early stages of cell transformation, which allows cells to later become aneuploid, thus leading to cancer progression. On the other hand, other studies convey that polyploidy plays a tumor suppressor role, by inducing cell cycle arrest, cell senescence, apoptosis, and even prompting cell differentiation, depending on the tissue cell type. There is still a gap in understanding how cells that underwent WGD can overcome the deleterious effect on cell fitness and evolve to become tumoral. Some laboratories in the chromosomal instability field recently explored this paradox, finding biomarkers that modulate polyploid cells to become oncogenic. This review brings a historical view of how WGD and polyploidy impact cell fitness and cancer progression, and bring together the last studies that describe the genes helping cells to adapt to polyploidy., This research was funded by the Spanish Ministry of Science and Innovation MCIN/AEI/FEDER (doi:10.13039/501100011033) grants RTI2018-095496-B-I00 and PID2021-125705OB-I00, and by the Spanish Association Against Cancer (AECC) Scientific Foundation grant LABAE16017DECA. NS-G is funded by MCIN/AEI/FEDER (doi:10.13039/501100011033), under the Juan de la Cierva Postdoctoral program (FJC2020-044620-I). MG-A is funded by the Comunidad de Madrid Regional Government (PEJ-2020-AI/BMD-18019)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

TPX2 overexpression promotes sensitivity to dasatinib in breast cancer by activating YAP transcriptional signaling

  • Marugan, Carlos
  • Sanz-Gómez, Natalia
  • Ortigosa, Beatriz
  • Monfort-Vengut, Ana
  • Bertinetti, Cristina
  • Teijo, Ana
  • González, Marta
  • Alonso, Alicia
  • Lallena, María José
  • Moreno-Bueno, Gema
  • Cárcer, Guillermo de
Chromosomal instability (CIN) is a hallmark of cancer aggressiveness, providing genetic plasticity and tumor heterogeneity that allows the tumor to evolve and adapt to stress conditions. CIN is considered a cancer therapeutic biomarker because healthy cells do not exhibit CIN. Despite recent efforts to identify therapeutic strategies related to CIN, the results obtained have been very limited. CIN is characterized by a genetic signature where a collection of genes, mostly mitotic regulators, are overexpressed in CIN-positive tumors, providing aggressiveness and poor prognosis. We attempted to identify new therapeutic strategies related to CIN genes by performing a drug screen, using cells that individually express CIN-associated genes in an inducible manner. We find that the overexpression of targeting protein for Xklp2 (TPX2) enhances sensitivity to the proto-oncogene c-Src (SRC) inhibitor dasatinib due to activation of the Yes-associated protein 1 (YAP) pathway. Furthermore, using breast cancer data from The Cancer Genome Atlas (TCGA) and a cohort of cancer-derived patient samples, we find that both TPX2 overexpression and YAP activation are present in a significant percentage of cancer tumor samples and are associated with poor prognosis; therefore, they are putative biomarkers for selection for dasatinib therapy., This study has been supported by the following grants: From the “Ministerio de Ciencia, Innovación, Agencia Estatal de Investigación MCIN/AEI/FEDER” (http://doi.org/10.13039/501100011033): RTI2018-095496-B-I00 and PID2021-125705OB-I00 (GdC); PID2019-104644RB-I00 & PID2022-136854OB-I00 (GM-B); Juan de la Cierva Postdoctoral program FJC2020-044620-I (NS-G). From the Spanish Association Against Cancer (AECC) Scientific Foundation: LABAE16017DECA (GdC); PROYE19036MOR (GMB); POSTD234371SANZ (NS-G). From the Spanish National Research Council (CSIC): 2018-20I114, 2021-AEP035, and 2022-20I018 (GdC). From the Instituto de Salud Carlos III – CIBERONC: CB16/12/00295 (GM-B)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Osmotic stress influences microtubule drug response via WNK1 kinase signaling

  • Monfort-Vengut, Ana
  • Sanz-Gómez, Natalia
  • Ballesteros-Sánchez, Sandra
  • Ortigosa, Beatriz
  • Cambón, Aitana
  • Ramos, María
  • Montes-San Lorenzo, Ángela
  • Escribano-Cebrián, María
  • Rosa-Rosa, Juan M.
  • Martínez-López, Joaquín
  • Sánchez-Prieto, Ricardo
  • Sotillo, Rocío
  • Cárcer, Guillermo de
Ion homeostasis is critical for numerous cellular processes, and disturbances in ionic balance underlie diverse pathological conditions, including cancer progression. Targeting ion homeostasis is even considered as a strategy to treat cancer. However, very little is known about how ion homeostasis may influence anticancer drug response. In a genome-wide CRISPR-Cas9 resistance drug screen, we identified and validated the master osmostress regulator WNK1 kinase as a modulator of the response to the mitotic inhibitor rigosertib. Osmotic stress and WNK1 inactivation lead to an altered response not only to rigosertib treatment but also to other microtubule-related drugs, minimizing the prototypical mitotic arrest produced by these compounds. This effect is due to an alteration in microtubule stability and polymerization dynamics, likely maintained by fluctuations in intracellular molecular crowding upon WNK1 inactivation. This promotes resistance to microtubule depolymerizing compounds, and increased sensitivity to microtubule stabilizing drugs. In summary, our data proposes WNK1 osmoregulation activity as an important modulator for microtubule-associated chemotherapy response., This study has been financed by the following grants: From the Ministerio de Ciencia, Innovación, Agencia Estatal de Investigación MCIN/AEI/FEDER UE (doi:10.13039/501100011033): RTI2018–095496-B-I00 and PID2021–125705OB-I00 (GdC); PID2021–122222OB-I00 (RSP); Juan de la Cierva Postdoctoral program FJC2020–044620-I (NSG). From the Spanish Association Against Cancer (AECC) Scientific Foundation: LABAE16017DECA (GdC) and POSTD234371SANZ (NSG). From the Spanish National Research Council (CSIC) with grants 201820I114, 2021-AEP035, 2022–20I018 (GdC), JAEINT_22_01172 (SBS), and JAEINT_24_01201 (MEC). From the UCLM with grant 2022-GRIN-34150 (RSP). EMBO Scientific Exchange Grant (SEG-9883) to AMV, in RS laboratory., Peer reviewed